Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
930.68B
Market cap930.68B
Price-Earnings ratio
35.57
Price-Earnings ratio35.57
Dividend yield
0.63%
Dividend yield0.63%
Average volume
3.06M
Average volume3.06M
High today
$989.22
High today$989.22
Low today
$986.92
Low today$986.92
Open price
$1,003.00
Open price$1,003.00
Volume
75.78K
Volume75.78K
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

Eli Lilly(LLY) stock is priced at $989.22, giving the company a market capitalization of 930.68B. It carries a P/E multiple of 35.57 and pays a dividend yield of 63.1%.

On 2026-05-19, Eli Lilly(LLY) stock traded between a low of $986.92 and a high of $989.22. Shares are currently priced at $989.22, which is +0.2% above the low and 0.0% below the high.

The Eli Lilly(LLY)'s current trading volume is 75.78K, compared to an average daily volume of 3.06M.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,133.95 and a 52-week low of $623.78.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,133.95 and a 52-week low of $623.78.

LLY News

Nasdaq 11h
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party

Key Points There is a need for more weight loss drug options, including oral pills. Viking Therapeutics is working on a promising one, though tolerability mig...

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party
The Motley Fool 13h
Eli Lilly Stock: Next Stop $2,000? - The Motley Fool

...

Eli Lilly Stock: Next Stop $2,000? - The Motley Fool
The Motley Fool 14h
Eli Lilly Stock: Next Stop $2,000?

It's been a volatile year for Eli Lilly (LLY 1.61%). The company's shares trended lower through the end of April, dropping well below $900. However, the drugmak...

Eli Lilly Stock: Next Stop $2,000?

Analyst ratings

85%

of 33 ratings
Buy
84.8%
Hold
12.1%
Sell
3%

More LLY News

24/7 Wall St. 18h
Three Biotechs That Are Top Takeover Targets

Three Biotechs That Are Top Takeover Targets By Alex Sirois Published May 18, 1:55PM EDT Quick Read Viking Therapeutics (VKTX) has a dual GLP-1/GIP agonist in...

Three Biotechs That Are Top Takeover Targets
Benzinga 18h
Supreme Court Rejects Eli Lilly Appeal In Medicaid Fraud Case

• Eli Lilly stock is trending lower. Why is LLY stock trading lower? The Bloomberg report on Monday noted that the justices issued the decision without comment,...

Supreme Court Rejects Eli Lilly Appeal In Medicaid Fraud Case
TipRanks 22h
Eli Lilly Dealt Blow as U.S. Supreme Court Refuses to Hear Whistleblower Law Challenge

Eli Lilly’s (LLY) stock is down 2% on news the U.S. Supreme Court has declined to hear a challenge by the company to a Civil War-era whistleblower law. Claim 55...

TipRanks 22h
Eli Lilly appeal to Supreme Court rejected

A writ of certiorari was denied by the U.S. Supreme Court in the case of Eli Lilly (LLY) v. Streck, Ronald J., meaning that the Court has declined to hear the a...

TipRanks 1d
Eli Lilly Is the Face of the Obesity Boom. Has the Market Already Priced It In?

Eli Lilly (LLY) has become the face of the global obesity drug boom, powered by its GLP-1 (glucagon-like peptide-1) based tirzepatide franchises Mounjaro and Ze...

Simply Wall St 3d
Eli Lilly Is Up 6.0% After Obesity Drug Data And $4.5B Manufacturing Push - Has The Bull Case Changed?

Earlier this week, Eli Lilly reported detailed late-phase obesity trial results showing long-term weight maintenance with injectable Zepbound and oral Foundayo,...

Eli Lilly Is Up 6.0% After Obesity Drug Data And $4.5B Manufacturing Push - Has The Bull Case Changed?
Simply Wall St 5d
Is It Too Late To Consider Eli Lilly After Its Strong Share Price Rally?

Wondering whether Eli Lilly's current share price still makes sense after a strong run, or if you might be paying too much for future expectations? This article...

Is It Too Late To Consider Eli Lilly After Its Strong Share Price Rally?

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.